Rate Video

EHA 2020 | Should we treat high-risk DLBCL differently?

Ulrich Jäger • 12 Jun 2020

Diffuse Large B-Cell Lymphoma Lymphoma Doxorubicin R-CHOP

Ulrich Jäger, MD, of Medical University of Vienna, Vienna, Austria, discusses the critical issue of whether we should treat high-risk diffuse large B-cell lymphoma (DLBCL) differently. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

The regulation of personalized medicine trials

Ulrich Jäger • 15 Jun 2019

Large networks in CLL research

Ulrich Jäger • 7 Oct 2020

The SADAL study: selinexor for R/R DLBCL

Ulrich Jäger • 17 Dec 2020

Practical aspects of CAR T-cell therapy

Ulrich Jäger • 9 Feb 2021

Related Videos

First-line axicabtagene ciloleucel in lymphoma

Yago Nieto • 15 Feb 2021

Cord blood-derived NK cells with high-dose chemotherapy & ASCT for B-NHL

Yago Nieto • 15 Feb 2021

Infusion of CD30 CAR T-cells following AuHCT in patients with lymphoma

Marcie Riches • 15 Feb 2021

Future directions of immune cell therapy in lymphoma

Yago Nieto • 15 Feb 2021